Board of Directors

Disclosure Information

Our board of directors has tremendous passion for our cause. Their expertise drives our mission and truly forms the foundation of our leadership.

Thomas Roberts, Jr.

Thomas G. Roberts, Jr., MD, FASCO

Chair

Chair

Dr. Roberts is a Managing Member and portfolio manager at Farallon Capital Management, LLC. Prior to joining Farallon, Dr. Roberts was an attending oncologist at Massachusetts General Hospital, an Instructor of Medicine at the Harvard Medical School, and a Visiting Scientist at Massachusetts Institute of Technology. Dr. Roberts obtained two baccalaureate degrees (Summa Cum Laude) from the University of Pennsylvania, including a Bachelors of Science from the Wharton School of Business (Phi Beta Kappa junior year). He obtained his medical degree from Harvard Medical School. Dr. Roberts performed his internal medicine training at the Massachusetts General Hospital and his medical oncology training through the Dana-Farber/Partners Cancer Care Oncology Fellowship Program. Dr. Roberts has been an ASCO member since 2003.

Dr. Susan Swain

Sandra M. Swain, MD, FACP, FASCO

Treasurer

Treasurer

Sandra M. Swain, MD, FACP, FASCO is a Professor of Medicine and the Associate Dean for Research Development at the Georgetown University Medical Center (GUMC) in Washington, DC. She is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences. In her primary role as Associate Dean for Research Development, Swain works closely with industry and community partners to improve patients’ access to cutting-edge treatments and technologies by expanding medical research opportunities both at GUMC and across the MedStar Health system as a whole. Previously, for over nine and a half years, Swain served as the Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center in Washington, DC. She has also served at the National Institutes of Health as the Deputy Branch Chief for the Medicine Branch of the Center for Cancer Research at the National Cancer Institute (NCI) with tenure as a Principal Investigator. At the NIH, she was the Head of the Breast Cancer Section, and Chief of the Cancer Therapeutics Branch. She graduated with a Bachelor of Arts (B.A.) in Chemistry from the University of North Carolina in 1975 and earned her Doctor of Medicine (M.D.) from the University of Florida in Gainesville in 1980. She completed a residency in Internal Medicine at Vanderbilt University in 1983 followed by a fellowship in Medical Oncology at the NCI in 1986.

Swain’s research interests include translational research and clinical trials focused on metastatic and inflammatory breast cancer, adjuvant therapy for breast cancer, cardiotoxicity, and health care disparities. Her research has received funding from the National Institutes of Health, Susan G. Komen Foundation, Breast Cancer Research Foundation, and the Avon Foundation. She has published over 250 articles and is internationally recognized as a leader in the field breast cancer research and treatment. Moreover, Swain has received numerous awards and recognitions for her work, including the Susan G. Komen Award of Distinction for Community Service in 2012. She is also a recipient of the National Institutes of Health Merit Award, as well as a two-time recipient of the National Cancer Institute Mentor of Merit Award. In 2012, she also received the Claude Jacquillat Award for Clinical Cancer Research and in 2016, the Washington Business Journal honored Swain with its prestigious Women Who Mean Business award.

Swain served as President of the American Society of Clinical Oncology (ASCO) from 2013-14. She is currently a member of the Conquer Cancer Foundation Board of Directors and was previously a member of the ASCO Board of Directors. She also sits on the Executive Committee of the Lombardi Comprehensive Cancer Center at GUMC. She has actively contributed to the National Surgical Adjuvant Breast and Bowel Project for over 25 years and is an active member of the NRG Breast Committee. She is also a Fellow of the American College of Physicians and a member of both the American Association of Cancer Research and the American Medical Association.

Alex Casdin

Alexander Casdin

Secretary

Secretary

Alex Casdin, founder of Reneo Capital Management LP, is a successful healthcare investor and executive with over 20 years of experience in leadership roles: investment, operational and advisory.  From October 2012 to December 2013, Mr. Casdin was a private healthcare investor and served as a healthcare company Board Member.  From October 2011 through September 2012, he was the Chief Financial Officer of Sophiris Bio.  Prior to Sophiris, Mr. Casdin served as the Vice President, Finance of Amylin Pharmaceuticals, a position he held from 2009 to 2011.  Prior to his position at Amylin, Mr. Casdin ran Casdin Advisors LLC, where he served as a strategic advisor to companies in the life sciences industry, including Amylin. 

Before founding Casdin Advisors, Mr. Casdin was the Chief Executive Officer and Portfolio Manager of Cooper Hill Partners, LLC, a healthcare investment fund.  He joined Cooper Hill in September 2001 from Pequot Capital Management, where he managed $1.4 billion as the Portfolio Manager of the Pequot Healthcare Fund.  Prior to Pequot, Mr. Casdin worked at the Dreyfus Corporation as a senior managing analyst covering pharmaceuticals, biotechnology, and medical device companies.  He has also served as a Legislative Assistant to Congressman Robert J. Mrazek (D-NY) and then as a Legislative Affairs Specialist for Patton Boggs LLP in Washington, D.C.  Mr. Casdin received an M.B.A., Beta Gamma Sigma, from Columbia Business School and A.B. in Political Science from Brown University.  He served as a Advisor, and then Board Member and Audit Committee Chair of Ignyta Inc. (RXDX) from 2012 until it was acquired in February of 2018 by Roche for $1.7 billion.  He currently serves as an Advisor to Luna DNA, a Board Member of DiaVacs and Erasca. Mr. Casdin is a Board Member and on the Executive Committee of The Conquer Cancer Foundation of the American Society of Clinical Oncology, a member of the Advisory Board of the Social Enterprise Program at Columbia Business School, a member of the External Advisory Board, Center for Biomedical Engineering at Brown University’s School of Engineering as well as a member of the University’s President’s Leadership Council and a member of the Advisory Board of the Hassenfeld Children’s Center for Pediatric Oncology and Blood Disorders at NYU Langone Medical Center.

Dr. Clifford Hudis

Clifford A. Hudis, MD, FACP, FASCO

ASCO CEO and Conquer Cancer CEO (ex-officio)

ASCO CEO and Conquer Cancer CEO (ex-officio)

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of the American Society of Clinical Oncology and the CEO of the Conquer Cancer Foundation. Previously he served for nearly two decades as the Chief of the Breast Medicine Service and Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City where he was also a Professor of Medicine at the Weill Medical College of Cornell University. He was co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group), Chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation, a former Associate Editor of the Journal of Clinical Oncology, and the President of ASCO during its 50th anniversary year, 2013-2014.

For almost 30 years he worked to develop more effective treatment and prevention for breast cancer. His early work focused on translating the kinetic predictions of the Norton-Simon model into more effective dose-dense adjuvant chemotherapy programs. For the past decade he has studied the interplay of inflammation, obesity, and cancer and his group described low grade, chronic white adipose inflammation in most overweight and obese women. His group has made similar observations in other malignancies and risk groups and have used these insights to inform intervention studies and public policy initiatives at an international level.

Howard A. (Skip) Burris III, MD

Howard A. Burris III, MD, FASCO, FACP

ASCO President (ex-officio)

ASCO President (ex-officio)

Howard A. "Skip" Burris III, MD, FASCO, FACP serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr. Burris will serve as the elected president of ASCO in 2019-2020. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor. 

Nancy R. Daly, MS, MPH

Nancy R. Daly, MS, MPH

Chief Philanthropic Officer (ex-officio)

Chief Philanthropic Officer (ex-officio)

Ms. Daly is the Executive Vice President & Chief Philanthropic Officer of the Conquer Cancer Foundation. She launched her clinical nursing career at Johns Hopkins Oncology Center. Following graduate school at Columbia University, she stayed on as Director of Operations in the Radiation Oncology Department before resuming her clinical career as Director of the Chemical-modifier Program at the Joint Center for Radiotherapy at Harvard Medical School. Leaving the clinical world, Nancy started her policy career with the American Society for Radiation Oncology as the Director of Government Relations. Nancy joined ASCO as Director of Cancer Research Policy in 2004, later becoming Director of Grants for The ASCO Cancer Foundation, the precursor to the Conquer Cancer Foundation. She has served as Executive Vice President of the Foundation since 2009.

Monica Bertagnolli

Monica M. Bertagnolli, MD, FACS, FASCO

Monica M. Bertagnolli, MD, FACS, FASCO, is a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has worked at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital since 2000. She previously served as an associate surgeon at the Strang Cancer Prevention Center in New York from 1994-2007 and as an attending surgeon at New York Presbyterian Hospital–Cornell from 1994-1999.

Since joining ASCO in 1995, Dr. Bertagnolli has served on the Board of Directors (2007-2011), as well as on numerous committees, including the ASCP/CAP/AMP/ASCO Colorectal Cancer Guidelines Committee (co-chair 2011-present), the Cancer Prevention Committee (2001-2004 and 2007-2010), and the Planning Committee (2008-2011), among others.

In addition to her ASCO involvement, Dr. Bertagnolli currently serves as vice president of Coalition of Cancer Cooperative Groups, group chair of Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. Since 2012 she has served on the National Academy of Medicine’s National Cancer Policy Forum. In 2011, she received the Partners Healthcare Partners in Excellence Award: Personalized Cancer Medicine Partnership Team, and in 2015, she received the CEO Roundtable on Cancer Charles H. Sanders Life Sciences Award.

Dr. Bertagnolli received her undergraduate degree from Princeton University and her medical degree from the University of Utah College of Medicine; she performed her residency at Brigham and Women’s Hospital.

Riccardo

Riccardo Braglia

Riccardo Braglia, Helsinn Group’s Vice Chairman and CEO, Managing Director and Member of Helsinn Holding’s Board of Directors, Switzerland and Executive Committee for Helsinn Group’s strategic management, has a wealth of over 30 years of international experience in the pharmaceutical industry. Mr. Braglia heads the family-run, privately-owned pharmaceutical company, the Helsinn Group, founded in 1976, with a worldwide presence and focus on oncology therapeutics and supportive care, which is strongly committed to improving the everyday lives of people with cancer.
 
Riccardo Braglia is Board Member of Helsinn Healthcare, Switzerland, Helsinn Advanced Synthesis, Switzerland, Helsinn Birex Pharmaceuticals, Ireland and Chairman of Helsinn Therapeutics, USA. He is also Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco and Chairman of Helsinn Investment Fund, Luxembourg. He is also Co-founder and Board Member of Lyfebulb, U.S.A., Board Member of Thorne Research, Greenwich CT/U.S.A., Wellness-Fx and Health Elements.com.  Mr. Braglia is also active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures. 

Riccardo Braglia holds a degree in Business Economics with specialization in Business Industrial Management from the Luigi Bocconi University of Milan, Italy

Susan L. Cohn, MD, FASCO

Susan L. Cohn, MD, FASCO

Dr. Cohn, a pediatric oncologist at the University of Chicago, has devoted her career to developing more effective treatments for children with neuroblastoma, a common pediatric cancer with a broad spectrum of clinical behavior ranging from spontaneous regression to relentless tumor growth. In 2000, Dr. Cohn was appointed the first chair of the Children’s Oncology Group (COG) Neuroblastoma Disease Committee, and under her leadership, a series of risk-based clinical trials were conducted, resulting in significant reductions in treatments for children with low- and intermediate-risk disease and improved survival for high-risk patients.  In addition, Dr. Cohn has worked with Andrew Pearson, MD, MBBS, of The Royal Marsden NHS Foundation Trust, in the United Kingdom, and colleagues to develop an International Neuroblastoma Risk Group (INRG) Classification System and the INRG Data Commons which contains data on more than 18,000 children diagnosed with neuroblastoma around the world that is available for research studies. Dr. Cohn is the current Dean for Clinical Research in the Biological Services Division at the University of Chicago and  Chief of the Section of Pediatric Hematology/Oncology.  Dr. Cohn has been a member of ASCO since 1988 and has served on ASCO’s Board of Directors and is a past ASCO Treasurer.

Lawrence H. Einhorn, MD, FASCO

Lawrence H. Einhorn, MD, FASCO

Dr. Einhorn is a distinguished professor of medicine and the Livestrong Foundation Professor of Oncology at the Indiana University School of Medicine, and a physician-researcher at Indiana University Melvin and Bren Simon Cancer Center, in Indianapolis, Indiana. His work has garnered many accolades, including American Society of Clinical Oncology Karnofsky Award, American Cancer Society Medal of Honor, American Association for Cancer Research Joseph H. Burchenal Memorial Award and Richard and Hinda Rosenthal Memorial Award, and the General Motors Kettering Prize. Dr. Einhorn’s clinical interests include solid tumor oncology, specifically within the fields of genitourinary and lung cancers. Dr. Einhorn revolutionized testicular cancer treatment through his research on platinum combination chemotherapy in patients with metastatic testicular cancer. He received his medical degree from the University of Iowa in Iowa City, and completed fellowships at The University of Texas MD Anderson Cancer Center in Houston, Texas, and the Indiana University Medical Center in Indianapolis. Dr. Einhorn has published more than 450 peer-reviewed articles. In addition, Dr. Einhorn is a member of the National Academy of Sciences and American Philosophical Society.

claire huang

Claire A. Huang

Ms. Huang is an established leader in the fields of marketing, communications, and brand management. Most recently she served as the first Chief Marketing Officer for JP Morgan Chase, where she worked with the marketing teams across all Chase retail and JP Morgan wholesale business to build brands with a client/customer focus. Her marketing background is extensive, and she has held executive-level positions at Bank of America Merrill Lynch, Fidelity Investments, and American Express. Earlier in her career, she developed her credentials as a turnaround and growth expert in a succession of consumer products companies beginning at Procter and Gamble. Claire is currently on the Board of Directors of Foster Farms poultry company. She also serves on the US Leadership Council of Cordaid, a global non-profit whose goal is to help build flourishing communities under the most difficult circumstances. Claire serves on the Advisory Board of the South Bronx Educational Foundation and she founded The Fisherman Foundation, a non-profit organization that helps individuals of modest means become self- sufficient.

Raj Mantena, RPh

Raj Mantena, RPh

It is a challenge faced time and time again by oncologists: how to achieve the best possible outcomes for patients while simultaneously controlling costs, providing care that is both high quality and high value. Raj Mantena, RPh, the first individual to donate $1 million dollars to the Conquer Cancer Foundation, has spent his career wrestling with that challenge. Find out why Raj decided to make such a generous gift to Conquer Cancer.

Thomas A. Marsland, MD, FASCO

Thomas A. Marsland, MD, FASCO

Dr. Marsland recently joined St. Joseph Health System in California, where he continues his medical oncology practice in their Petaluma satellite office. Prior to his move west, which he made in order to be closer to his children and grandchild, Dr. Marsland was an active participant in several regional oncology organizations in Florida. He served on the Association of Community Cancer Centers Membership and Public Affairs Committees, as well as the Oncology Issues editorial board. He was as a managing partner in his Florida practices and was active at a state level in organized medicine, having served as president of the state society twice. Dr. Marsland was involved in volunteer work, serving as president for the local and Florida division units of ASC. Nationally, he served on the boards of ACCC and ASCO, as well as multiple committees. Today, he continues his service on the Board of Directors of the Conquer Cancer Foundation, an affiliate of ASCO.

Robert J. Mayer, MD, FASCO

Robert J. Mayer, MD, FASCO

Dr. Mayer is Faculty Vice President for Academic Affairs at the Dana-Farber Cancer Institute, Senior Physician at Brigham and Women’s Hospital, , and the Stephen B. Kay Professor of Medicine at Harvard Medical School, where he is also Faculty Associate Dean for Admissions.  He directed the Institute’s Medical Oncology Fellowship Program for more than 30 years, overseeing the training of several hundred oncologists. Dr. Mayer’s research interests focus on gastrointestinal cancer, a subject about which he has published extensively. He has served as an Associate Editor for the New England Journal of Medicine and the Journal of Clinical Oncology, is a past president of ASCO, and is a former member of the Executive Committee of the American Board of Internal Medicine. Dr. Mayer is a graduate of Williams College and the Harvard Medical School.

Gerald J. McDougall

Gerald J. McDougall

Gerry is a principal in PwC’s Health Sciences Practice serving academic and research organizations across the healthcare continuum. Gerry joined the firm in 1988. He is responsible for leadership of the broad range of basic, translational and clinical research strategic and business planning services that PwC provides to academic and research organizations, specializing in development of synergistic partnerships and creation of new research ventures.  Gerry serves as Partner on large engagements involving senior-level clients and interacts with the institution’s Board, financial leaders and political stakeholders.  Gerry's clients have included many of the top 50 Academic Medical Centers, major research universities and health systems, biotech organizations and pharmaceutical/device companies.

  • Leads PwC’s  US Oncology Practice serving academic  and commercial research organizations across the healthcare continuum and is responsible for leadership of the broad range of basic, translational and clinical research strategic and business planning services that PwC provides to academic and research organizations.  Specializes in development of partnerships and creation of new research ventures. 
  • Over the last decade of Gerry's leadership of the Health Sciences practice, clients have included CEO's, Presidents, Boards of Directors, prominent scientific leadership including Nobel Laureates, National Academy members, Lasker  Award recipients, leaders of patient advocacy groups, heads of R&D, Chief Scientific Officers, CMO's, the federal government and governors of several states.
  • Over the past 5 years, Gerry’s teams have helped secure billions of dollars for biomedical research and he has been instrumental in assisting prominent organizations such as the Knight Institute for Early Detection of Cancer and its clinical Director, Dr. Brian Druker, in developing strategies and plans to invest funds for the early detection of cancer.
  • Among many strategic goals, they have focused on several key areas including;
  • Identifying the current limits of sensitivity and specificity and determine how they can be markedly improved to advance early detection,
  • Drawing clear distinctions between technological limitations and barriers that can be overcome versus absolute physical limits that define the boundaries of what is technically possible,
  • Contemplating which technologies are best suited for individual tumors and which could be applied broadly,
  • Development of cohorts suited to evaluating novel early detection technologies; the current understanding of the biology of transition from pre-malignancies to lethal malignancies; and what can be learned about early cancer recurrence, its prediction and detection, and how these things may inform earlier detection technologies.
craig nichols

Craig R. Nichols, MD, FACP, FASCO

Dr. Nichols currently serves as a SWOG executive officer primarily responsible for research support committees, quality and innovation. In particular he is the executive liaison with Adolescent and Young Adult Oncology, Digital Engagement and Patient Advocacy Committees. He began his academic career on the faculty at Indiana University.  His mid-career was as division chief and Vice Chair of the Cancer Center at Oregon Health and Science University.  He has been involved in oncology leadership through board positions with Leukemia Lymphoma Society and LIVESTRONG. Since joining ASCO in 1986, Dr. Nichols has served the Society in numerous volunteer capacities, including as a member of the CancerLinQ Board of Governors and as ASCO Treasurer.

Dr. Charles Penley

W. Charles Penley, MD, FASCO

Chair Emeritus

Chair Emeritus

Dr. Penley has been a member of the Conquer Cancer Foundation Board of Directors since 2005.  He served as Chair from 2013-2015 and served as Treasurer from 2007-2012. A native Tennessean, he has been treating patients with cancer in Nashville for over 25 years. Dr. Penley is currently a partner with Tennessee Oncology, PLLC. He has been a member of ASCO since 1987, has served two terms as a presidentially-appointed member of the Clinical Practice Committee (CPC), and is former Chair of the CPC. He has served as a member of the Public Issues Committee’s subcommittee on Cancer Care at the End of Life, the Cancer Education Committee, the Special Awards Selection Committee and Immediate Past Chair of the Government Relations Committee. Dr. Penley serves on the Board of Trustees of the Association of Community Cancer Centers and is a member of the Dean’s Advisory Board of the College of Arts and Sciences at the University of Tennessee, Knoxville, where he earned his bachelor’s degree. He earned his medical degree from Wake Forest University’s Bowman Gray School of Medicine.

Steven T. Rosen, MD, FACP

Steven T. Rosen, MD, FACP, FASCO

Dr. Rosen is the Irell and Manella Professor and Inaugural Provost, Scientific and Cancer Center Director of the City of Hope. Previously he was the Genevieve  E. Teuton Professor of Medicine and Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Under his visionary leadership since 1989, Dr. Rosen brought the Lurie Cancer Center to a position of national prominence.  Dr. Rosen is recognized as a leading international figure in cancer care.  He continues to provide primary oncology care to patients with hematologic malignancies and breast cancer annually.    Dr. Rosen oversees a basic science laboratory and clinical research team that has advanced novel agents and technologies, which have influenced the management of patients with blood cancers. Dr. Rosen has published more than 400 original reports, editorials, books, and book chapters over his career that reflect his academic productivity and contributions to the field. His research has been funded by the National Cancer Institute (NCI), American Cancer Society (ACS), Leukemia & Lymphoma Society of America (LLS) and Multiple Myeloma Research Foundation (MMRF). Dr. Rosen is the current co-principal investigator of Northwestern’s NCI-funded Center for Cancer Nanotechnology Excellence, overseeing the clinical and biologic components of the grant. Dr. Rosen has served in an advisory capacity to the NCI, ACS, LLS and more than 20 distinguished cancer centers across the nation. He is highly regarded as an educator by his peers. He has trained more than two dozen graduate and post-graduate students and is the current principal investigator on two current NCI training grants.  Dr. Rosen also has served on numerous editorial boards and is current editor-in-chief for Cancer Treatment & Research. He is a recipient of the “Martin Luther King Humanitarian Award”, Northwestern Memorial Hospital and the distinguished “Alumni Merit Award” from Northwestern University. Dr. Rosen also is listed as one of “Chicago’s Top Doctors” and “America’s Top Doctors.” 

Margaret Tempero, MD, FASCO

Margaret Tempero, MD, FASCO

Dr. Tempero is Director, UCSF Pancreas Center. Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Currently her group is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. She is Chief Emeritus, Division of Medical Oncology at UCSF and was the founding Deputy Director and Director of Research Programs. Dr. Tempero is a past President of ASCO and recently served on the Oncology Drug Advisory Committee for the FDA. Dr. Tempero is Editor In Chief – JNCCN and Chair - NCCN Pancreas Cancer Guidelines Panel.